期刊
BLOOD REVIEWS
卷 43, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2019.100650
关键词
Acute myeloid leukemia; MRD; Minimal residual disease; Immune checkpoint; Next generation sequencing
类别
资金
- NCI's Cancer Clinical Investigator Team Leadership Award (CCITLA)
- National Cancer Institute of the National Institutes of Health [P30 CA016359]
- State of Connecticut under the Regenerative Medicine Research Fund
- NIH/NIDDK [R01DK102792]
- Edwards P. Evans Foundation
- Frederick A. Deluca Foundation
- Leukemia Lymphoma Society
- Department of Defense Cancer Research Program
- DeLuca Center for Innovation in Hematology Research at Yale Cancer Center
Patients with acute myeloid leukemia (AML) who achieve morphologic remission in the bone marrow after initial treatment often continue to harbor residual leukemic cells that can give rise to disease relapse. Achievement of a deeper remission has been associated with a reduced risk of relapse and improved event-free and overall survival in several studies. However, standardization of diagnostic techniques, sample acquisition and test timing are needed before minimal, also known as measurable, residual disease (MRD) quantification can be used to guide treatment decision making. Furthermore, clinical trial evidence that preemptive intervention at MRD level can alter the natural history of AML is required. Herein, we outline the current landscape of MRD assessment in AML, summarize the available evidence and challenges, and highlight the potential for MRD status to serve as a surrogate endpoint for hard clinical outcomes and as an approvable endpoint in clinical trials for regulatory purposes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据